#United States #New York #5Q Spectra #Prostate Dx #PSB Blood Test

Groundbreaking Prostate Cancer Blood Test Unveiled

On September 14, the Davos of Healthcare Summit in New York City will host the global unveiling of 5Q Spectra's innovative Prostate Dx™ test, known as the PSB blood test (Prostate Specific Biomarker test). This launch signifies a pivotal moment in the company's journey over the past 15 years toward enhancing blood-based cancer diagnostics.

This summit, recognized for uniting leading hospitals, scientists, and biotech innovators focused on transforming breakthrough research into practical medical solutions, will showcase a revolutionary development in the diagnosis of prostate cancer. The Prostate Dx™ test aims to address a significant healthcare challenge related to the diagnosis of prostate cancer. Elevated PSA levels have long been the primary alarm signal for prostate cancer; however, they are not definitive. Other non-cancerous conditions can also raise PSA levels, leading many men to experience unnecessary psychological distress and undergo invasive procedures without confirmation of cancer.

Ransel N. Potter, the Founder of the summit, emphasized the importance of this moment in medical science. He stated, “Davos of Healthcare brings extraordinary medical science and clinical leadership to a global healthcare stage. 5Q Spectra's new 'PSB' blood test is addressing a critical diagnostic gap, helping patients navigate the uncertainty surrounding elevated PSA levels.”

5Q Spectra's dedication to resolving this issue has involved over C$85 million in research and development investment. Their newly developed PSB blood test offers impressive diagnostic reliability, achieving an AUC score of 0.86, which can increase to approximately 0.92 when paired with imaging and their clinical-intelligence AI platform. At a selected high-sensitivity threshold, the test boasts around 95% sensitivity, potentially eliminating up to 44% of unnecessary surgical biopsies that have plagued patient care.

Steve de Jaray, Co-Founder and CEO of 5Q Spectra, remarked, “While elevated PSA levels tell us when further investigation is warranted, they were never designed to inform us whether prostate cancer actually exists. Our PSB blood test seeks to provide better cancer-specific biological insights when alarm signals are triggered.”

The Davos Summit will also feature a panel of experts in urology, radiation oncology, prostate surgery, and a prostate cancer survivor. The panel will discuss the medical science underpinning prostate cancer detection and the PSB blood test's role in contemporary urologic oncology practices.

In summary, 5Q Spectra's Prostate Dx™ test represents a major advancement in the fight against prostate cancer, providing men with the necessary tool to make informed healthcare decisions based on accurate diagnostic information. As the inaugural launch approaches, the medical community looks forward to the promise this test holds in transforming prostate cancer diagnosis and patient management.

About C³ Davos of Healthcare™

C³ gathers leaders in healthcare, science, and international business, fostering collaboration and the commercialization of innovative health solutions.

About 5Q Spectra Corp.

5Q Spectra is a pioneer in developing blood-based molecular diagnostics aimed at facilitating early and actionable cancer detection. The Prostate Dx™ / PSB test is currently operational and available as a Laboratory Developed Test (LDT) through certified laboratory networks.